Arresto BiosciencesTM is a biotech company that develops medicines to treat cancer and fibrotic diseases by targeting extracellular matrix proteins. Changes in the normal composition of the extracellular matrix of healthy tissues appear to play a role in the etiology of cancer and diseases with a fibrotic contribution such as liver cirrhosis, pulmonary fibrosis and scleroderma. The treatment of cancer and fibrotic diseases pose a huge unmet clinical need. Drugs that interact with components of the extracellular matrix could offer a treatment option for millions of patients worldwide.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 12/31/07 | Series A | 16M | Vaizra Investments, The Slater Technology Fund | Unknown |
People
Victoria Smith (SVP R&D)
Augustine Lawlor (Board Member)
Hector Rodriguez (scientist)
Scott Ogg (Director of Project & Alliance Management)
Joseph Lacob (Board Member)
News
Arresto lands funds to treat cancer and fibrotic disease
March 4, 2009 8:49 am
Arresto Biosciences, maker of a drug that targets both cancer and fibrotic diseases, just landed an undisclosed third round of… Continue reading ⟩
Arresto Biosciences, cancer-drug developer, raises funds
February 28, 2008 2:55 pm
See our story about this Palo Alto, Calif., biotech in Wednesday’s daily briefing at VentureBeat Life Sciences. Continue reading ⟩
Life sciences briefing: Wednesday, Feb. 27, 2008
February 27, 2008 1:08 pm
TODAY’S HEADLINES: InSound Medical raises $11M for “invisible” hearing aids (VBLS exclusive) Corventis takes in $20M for heart-failure therapy (VBLS… Continue reading ⟩